Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016

Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016
Published Jun 28, 2016
72 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016, provides in depth analysis on Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein)
- The report reviews Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product

  
Source:
Document ID
GMDHC0128TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Overview71
Therapeutics Development83
  Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Products under Development by Stage of Development81
  Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Products under Development by Therapy Area91
  Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Products under Development by Indication101
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Products under Development by Companies132
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Therapeutics Assessment156
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action161
  Assessment by Route of Administration172
  Assessment by Molecule Type192
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Companies Involved in Therapeutics Development215
  Alteogen Inc.211
  Chengdu Kanghong Pharmaceuticals Group Co., Ltd.221
  Clearside BioMedical, Inc.231
  Formycon AG241
  Regeneron Pharmaceuticals, Inc.251
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Drug Profiles2631
  (aflibercept + nesvacumab) Drug Profile261
  (aflibercept + rinucumab) Drug Profile272
  (aflibercept + triamcinolone acetonide) Drug Profile293
  aflibercept Drug Profile3211
  aflibercept biosimilar Drug Profile431
  aflibercept biosimilar Drug Profile441
  conbercept Drug Profile452
  SL-002 Drug Profile471
  SL-186 Drug Profile481
  SL-188 Drug Profile491
  THR-317 Drug Profile503
  ziv-aflibercept (recombinant) Drug Profile534
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Dormant Projects571
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Discontinued Products581
Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) Featured News &Press Releases5912
  Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists guidance591
  May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma601
  Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion611
  Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403611
  Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven621
  Feb 29, 2016: Formycon discloses details on second pipeline product FYB203 is a biosimilar for Eylea (aflibercept)631
  Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403631
  Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration641
  Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization651
  Sep 25, 2015: Bayer s Eye Drug Recommended for EU Approval in Fifth Indication651
  Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema661
  Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition671
  Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan671
  Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance681
  May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice683
Appendix712
  Methodology711
  Coverage711
  Secondary Research711
  Primary Research711
  Expert Panel Validation711
  Contact Us711
  Disclaimer721

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Placental-Growth-Factor-PIGF-or-Vascular-Endothelial-Growth-Factor-Related-Protein-Pipeline-Review-H1-2016-2088-16036>
  
APA:
Global Markets Direct - Market Research. (2016). Placental Growth Factor (PIGF or Vascular Endothelial Growth Factor Related Protein) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Placental-Growth-Factor-PIGF-or-Vascular-Endothelial-Growth-Factor-Related-Protein-Pipeline-Review-H1-2016-2088-16036>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.